Amgen’s Prolia, Xgeva Biosimilar Lawsuits Centralized in N.J.

Amgen Inc. convinced a judicial panel to centralize four federal lawsuits accusing biosimilar-drug makers of infringing patents for Prolia and Xgeva, its blockbuster bone-strengthening treatments.

Federal cases Amgen filed last year against Fresenius SE & Co. in Illinois and against Intas Pharmaceuticals Ltd. in North Carolina will continue in the US District Court for the District of New Jersey, Chair Karen K. Caldwell wrote in an order issued Thursday for a panel of five federal judges at the US Judicial Panel on Multidistrict Litigation. Those suits will merge with pending suits against Celltrion Inc. and Samsung Biologics Co. before Judge ...